pioneer of in silico medicine
Nova Discovery simulates clinical trials with virtual patients to de-risk research programs and optimize clinical development. With AI and virtual populations at the heart Nova’s in silico clinical trials platform Jinkō, Nova builds mathematical models of disease and treatment to optimise trial design, to capture best responders, and to demonstrate value to payers. The company is headquartered in Lyon, France.View website
Why we invested in Novadiscovery
The pharma industry wants to contribute to making healthcare more affordable for patients, but the ever increasing regulatory requirements, lengthening timelines and skyrocketing cost of drug development do not make this an easy job. Nova introduces a new category, in silico clinical trials, that reduces the need for trial and error, helping pharma to focus on those treatments that more likely work for given patient groups. As model informed drug development has become a strategic priority also for reglators worldwide, Debiopharm wanted to partner with the best and build the future together.
Discover how we can help you bring your ambition to life
Meet François-Henri Boissel
CEO and Founder of Novadiscovery
This French native launched his company Novadiscovery in response to an insight about the exponential growth of scientific information. When his company reached a scale up stage for its in silico clinical trial platform, Francois-Henri sought out both financial and strategic investment. In January 2020, Debiopharm led the Series A round, establishing an ongoing collaborative business relationship. Learn more about CEO, François-Henri Boissel’s start-up journey.
December 16, 2021
Novadiscovery expands Janssen collaboration
March 26, 2021
Novadiscovery announces new clinical simulation collaboration with Takeda
February 16, 2021
Novadiscovery closes a SerA extension, Sanofi invests €2.5M to advance the clinical trial simulation platform JINKO
January 9, 2020
Novadiscovery raises series A financing to scale its in silico clinical trial platform – Debiopharm leads the round with EUR…